Ulcerative Colitis Clinical Trial
Official title:
Prevalence of Graves Disease in Patients With Ulcerative Colitis
Graves disease in ulcerative colitis:
The connection between Graves disease and Inflammatory bowel disease is well known in the
literature, but thyroid disorders have not been considered extra-intestinal manifestations of
ulcerative colitis. In most cases, the diagnosis of thyroid disease has preceded that of
Inflammatory bowel disease. Early studies have suggested a relationship between thyroid
abnormalities and ulcerative colitis . But it is still uncertain whether the coexistence of
Grave's and ulcerative colitis diseases is due to a specific reason or a coincidence.
Graves disease in ulcerative colitis:
The connection between Graves disease and Inflammatory bowel disease is well known in the
literature, but thyroid disorders have not been considered extra-intestinal manifestations of
ulcerative colitis. In most cases, the diagnosis of thyroid disease has preceded that of
Inflammatory bowel disease . Early studies have suggested a relationship between thyroid
abnormalities and ulcerative colitis .But it is still uncertain whether the coexistence of
Grave's and ulcerative colitis diseases is due to a specific reason or a coincidence.
Concomitant Graves disease and ulcerative colitis; In general, the pathophysiology of
ulcerative colitis is associated with theTh2 cytokine phenotype, and there is increased Th2
activity in Graves disease .Therefore, both Graves disease and ulcerative colitis are
associated with a Th1/Th2 imbalance, with a dominance of Th2 responses. reported on a
26-year-old female who had a flare-up of ulcerative colitis and hyperthyroidism that was
successfully treated with infliximab. In addition, they reported that theTh1/Th2 imbalance
was improved 2 weeks after the initiation of infliximab therapy. However, it is still unclear
whether Graves disease is an extra intestinal manifestation of ulcerative colitis or not
Restricted to ulcerative colitis only, we found OR significantly increased for Grave's
disease.
Increasing evidence suggests that Grave's disease (GD), an autoimmune thyroid disease (AITD)
that accounts for 60%-80% of hyperthyroidism cases, might be related to the abnormal genetic
expressions, imbalance of immune responses, increased Th2 activity and overgrowth of
intestinal bacteria. For instance, the prior literature showed that some genetic factors,
such as Human leukocytic antigen , PTPN22 and CTLA4, were associated with Graves disease
Other studies also observed that hyperthyroidism with autoimmune gastritis is usually
accompanied with low acid production that may subsequently lead to an overgrowth of
intestinal bacteria Therefore, it is plausible that hyperthyroidism might be one of the
potential risk factors for ulcerative colitis, because both ulcerative colitis and
hyperthyroidism are polygenic diseases and may share analogous mechanisms Furthermore,
genetic pathways and Th2-dominant immunological responses could contribute to the association
between ulcerative colitis and hyperthyroidism.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
| Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
| Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
| Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
| Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
| Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
| Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
| Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
| Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
| Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
| Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
| Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
| Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
| Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
| Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |